Norihito Nakata

Title: Norihito Nakata: Innovator in Radioisotope-Labeled Antibodies

Introduction

Norihito Nakata is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of medical diagnostics and treatment through his innovative work on radioisotope-labeled antibodies. With a total of 4 patents to his name, Nakata's inventions are paving the way for advancements in cancer diagnosis and therapy.

Latest Patents

Nakata's latest patents include a site-specific radioisotope-labeled antibody using an IgG-binding peptide. This invention relates to an IgG-binding peptide that comprises a ligand capable of binding to a radioactive metal nuclide. It also includes a conjugate of the IgG-binding peptide and IgG, as well as a radionuclide imaging agent or a diagnostic agent for cancer. Another notable patent is the RI-labeled humanized antibody, which is a conjugate of a chelating agent chelated with a radionuclide and an antibody. This invention is particularly useful for the treatment and diagnosis of diseases where MUC5AC is overexpressed, especially cancer.

Career Highlights

Throughout his career, Nakata has worked with notable organizations such as Nihon Medi-Physics Company, Limited and Kagoshima University. His work in these institutions has allowed him to collaborate with other experts in the field and further his research in radioisotope applications.

Collaborations

Some of Nakata's coworkers include Yoshinari Shoyama and Yuji Ito. Their collaborative efforts have contributed to the success of his innovative projects and patents.

Conclusion

Norihito Nakata's work in the field of radioisotope-labeled antibodies represents a significant advancement in medical technology. His inventions are not only innovative but also hold the potential to improve cancer diagnosis and treatment.